(5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol

(5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3‑phenyl‑1,6‑dioxa‑2‑azaspiro[4.5]dec‑2‑ene‑8,9,10-triol is a synthetic small molecule with a spirocyclic structure containing both oxygen and nitrogen heteroatoms. It has been studied as an experimental compound and is not approved for clinical use. The compound is known to act as an inhibitor of glycogen phosphorylase—specifically the muscle form—which plays a central role in glycogen catabolism by catalyzing the phosphorolytic cleavage of glycogen to produce glucose 1-phosphate. By inhibiting this enzyme's activity allosterically or competitively at its active site or regulatory sites (mechanism details may vary by analog), such compounds are investigated for their potential in modulating glucose homeostasis and could be relevant in metabolic disorders like diabetes mellitus[6][7][1].

Other names

(5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro(4.5)dec-2-ene-8,9,10-triolglucopyranosylidene-spiro-isoxazoline 4cglucopyranosylidene-spiro-isoxazoline4cglucopyranosylidene-spiro-isoxazoline-4c